Table 3.

Inflammation marker levels in cases and controls

Inflammation markersIntrabatch CV %Below LLD aCases (N = 230)Controls (N = 432)
Cases n (%)Controls n (%)Median (10%, 90%), pg/mLMedian (10%, 90%), pg/mL
Cytokines
 IL-1β15.913 (5.7)24 (5.6)0.8 (0.1, 4.8)0.7 (0.1, 3.2)
 IL-27.832 (13.9)64 (14.8)14.6 (0.1, 61.1)11.4 (0.1, 47.6)
 IL-45.09 (3.9)27 (6.3)47.6 (1.5, 611)21.6 (1.4, 414)
 IL-514.556 (24.3)100 (23.1)0.1 (0.0, 1.1)0.1 (0.0, 1.0)
 IL-66.27 (3.0)15 (3.5)7.0 (0.9, 52.9)4.8 (0.7, 42.8)
 IL-105.11 (0.4)1 (0.2)5.6 (2.1, 37.8)5.4 (2.1, 21.2)
 IL-12p402.40 (0)1 (0.2)163 (81.9, 418)152 (73.0, 335)
 IL-12p7013.829 (12.6)75 (17.4)0.8 (0.1, 13.1)0.6 (0.1, 6.9)
 IL-134.029 (12.6)61 (14.1)22.8 (0.1, 160)15.3 (0.1, 132)
 TNFα6.41 (0.4)0 (0)3.2 (1.7, 6.4)3.0 (1.7, 5.8)
Cytokine modulators
 IL-1Ra4.156 (24.3)103 (23.8)517 (83.9, 5,595)547 (83.9, 3,660)
 sIL-1Rll0.80 (0)0 (0)5,255 (3,245, 8,321)5,536 (3,061, 8,832)
 sIL-2Ra1.80 (0)2 (0.5)556 (331, 982)539 (311, 952)
 sIL-4R1.30 (0)1 (0.2)631 (420, 1,211)616 (400, 1,126)
 sIL-6R2.30 (0)0 (0)44,896 (28,730, 139,267)51,354 (27,632, 160,798)
 sTNF-R11.10 (0)0 (0)1,244 (815, 2,126)1,215 (813, 2,024)
 sTNF-R21.00 (0)1 (0.2)765 (428, 1,097)759 (411, 1,166)

NOTE: Measurements below the LLD were assigned the value at the midpoint between the LLD and zero unless more than 5% of samples were below the LLD, on which values were multiply imputed using maximum likelihood estimation (15).

  • aThe proportion of values below the LLD did not differ substantially across cohorts for any of the markers except IL-1β (below LLD for 9%–11% of NYUWHS and ORDET controls and 0% of NSHDS controls) and IL-2 (below LLD for 23%–28% of NYUWHS and ORDET controls and only 1% of NSHDS controls).